Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations
A partir des données des registres américains du cancer entre 2005 et 2012 et de données issues d'enquêtes nationales de santé, ces deux études analysent l'évolution de l'incidence du cancer de la prostate et de la prescription de tests PSA après la publication, en 2008, de recommandations d'un groupe d'experts sur le dépistage du cancer de la prostate
Prostate-specific antigen (PSA) screening is a widely debated practice in the United States, given that PSA screening can lead to the diagnosis of nonlethal prostate cancer and the harms associated with treatment of such disease. In this context, the 2008 US Preventive Services Task Force (USPSTF) panel recommended against PSA screening in men older than 75 years. This recommendation, however, has been ineffective at reducing the observed prevalence of PSA screening among older men. More recently, the USPSTF issued a grade D recommendation against PSA screening for all men, regardless of age.
JAMA , résumé, 2014